Novocure’s Optune Gio fails to show benefit at earlier stage

Novocure announced that its Phase III TRIDENT study failed to demonstrate statistical significance in overall survival when Optune Gio was used at an earlier disease stage. The result suggests the device does not provide benefit in this earlier-stage indication, likely impacting the company's development strategy and regulatory pathway for expanded labeling.